MedTrace Logo

Pilot Study of Metformin for Patients With Fanconi Anemia

NCT03398824 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-11-29

Study results available
· View outcomes & findings →

Summary

This is a single institution, open-label, single arm pilot study of Metformin in patients with Fanconi Anemia (FA) and cytopenias with the primary endpoint of hematologic response. This study will also assess safety, tolerability, and the biologic effects of Metformin in patients with FA.

Conditions

  • Fanconi Anemia

Interventions

DRUG

metformin HCl

Receive metformin HCl

Sponsors & Collaborators

Principal Investigators

  • Akiko Shimamura, MD, PhD · Boston Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-29
Primary Completion
2020-10-09
Completion
2020-10-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03398824 on ClinicalTrials.gov